CORAL SPRINGS, Florida,
February 20, 2013 /PRNewswire/ --
FinancialNewsMedia.com reports on active HealthCare Companies to
watch today: Crown Marketing, Herbalife Ltd. (NYSE: HLF), Novogen Ltd.
(NASDAQ: NVGN), GNC Holdings, Inc. (NYSE: GNC), Pfizer Inc. (NYSE:
PFE) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI).
Crown Marketing, currently trading on the OTCQB market, traded
over 880,000 shares yesterday, exceeding its average daily volume.
To see the latest news and charts for Crown, please go to
http://www.marketwatch.com/investing/stock/cwnm. News
issued this morning from Crown Marketing was the company announced
that patents for its Controlled Drug Delivery Technology (CDDT)
have been approved and registered in Mexico. Mexico's pharmaceutical industry
faces unique challenges. According to an American Enterprise
Institute study, Mexico's
$15.5 billion market is plagued by
counterfeit goods. Illicit activity in Mexico's pharmaceutical industry is estimated
at roughly USD 1.9 billion per
year-with counterfeiting representing 81 percent of that illicit
market. This is a situation where CWNM believes its unique
technology could have a significant impact. For more details
regarding Crown's CDDT applications, go to
http://crowncddt.com/technology/
To read all the latest headlines for Crown, go to
http://finance.yahoo.com/q/h?s=CWNM+Headlines
Herbalife Ltd. (NYSE: HLF) reported late yesterday the company's
fourth quarter net sales of $1.1
billion, reflecting an increase of 20 percent compared to
the same time period in 2011 on volume point growth of 18 percent.
Net income for the quarter of $117.8
million, or $1.05 per diluted
share, compares to 2011 fourth quarter net income of $105.4 million and EPS of $0.86, respectively. Herbalife shares
soared yesterday in trading after documents revealed corporate
raider Carl Icahn's huge stake in
the Los Angeles-based maker of
nutritional foods and supplements. Shortly after the opening
bell on Wall Street yesterday, Herbalife shares added $4.72, or 12.3%, to $42.99, closing at $39.74.
Novogen Ltd. (NASDAQ: NVGN) experience heavy trading in the
markets yesterday closing up over 200% on 2.29Million shares
traded. Novogen uses a virtual model in its approach to drug
discovery and development. The new lean corporate structure focuses
on its human capital in-place of expensive facilities and equipment
that can be outsourced. The drug discovery strategies and plans are
created in-house then executed by a number of leading external
research organizations. This affords Novogen immediate access to
cutting edge facilities, skills, equipment and scale-up processes.
This strategy drives efficiencies over the drug
discovery/development continuum.
GNC Holdings, Inc. (NYSE: GNC), hit a new 52-week high Tuesday
as it is closed at $42.19, above its
previous 52-week high with over 3.9 million shares traded as of the
close. Average volume has been two million shares over the
past 30 days. GNC, the nation's largest specialty retailer of
health and wellness products, announced yesterday that its
employees and customers donated a total of $3.1 million during these past few months to
support the St. Jude Children's Research Hospital Thanks and Giving
campaign. The campaign, now in its ninth year, builds
awareness of and raises funds for the lifesaving research and
treatment done at St. Jude to help children fighting cancer and
other deadly diseases.
Pfizer Inc. (NYSE: PFE), a biopharmaceutical company, engages in
the discovery, development, manufacture, and sale of medicines for
people and animals worldwide. Pfizer pushed the pharma
industry higher in trading yesterday making a featured drugs winner
for the day. By the end of trading, Pfizer rose 42 cents (1.5%) to $27.71 on average volume. Throughout the day,
28.4 million shares of Pfizer exchanged hands as compared to its
average daily volume of 32.5 million shares. The stock ranged in a
price between $27.38-$27.71 after
having opened the day at $27.40 as
compared to Friday's trading day's close of $27.29.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) is an innovative
drug discovery and development company seeking to discover, develop
and deliver to patients best-in-class medicines for diseases with
significant unmet need. Infinity combines proven scientific
expertise with a passion for developing novel small molecule drugs
that target emerging disease pathways. Infinity
Pharmaceuticals' shares spiked 16 percent Tuesday after Morgan
Stanley issued a bullish assessment of the Cambridge-based
company's prospects and pricing potential. As of Tuesday,
Morgan Stanley was promoting an "Overweight" recommendation to
investors in Infinity stock while also assigning the company a
$47 price-per-share target. Infinity
(Nasdaq: INFI) saw its stock rise to $41.48 a share yesterday before closing at
$41.10
FinancialNewsMedia.com
is leading provider of third party publishing &
news dissemination services. If you would like more information
regarding our news coverage solutions, please
visit http://www.financialnewsmedia.com
for more details.
DISCLAIMER: FN Media Group LLC (FNMG) is a third party
publisher and news dissemination service provider, which
disseminates electronic information through multiple online media
channels. FNMG is NOT affiliated in any manner with any
company mentioned herein. FNMG and its affiliated companies
are a news dissemination and financial marketing solutions provider
and are NOT a registered broker/dealer/analyst/adviser, holds no
investment licenses and may NOT sell, offer to sell or offer to buy
any security. FNMG's market updates, news alerts and
corporate profiles are NOT a solicitation or recommendation to buy,
sell or hold securities. The material in this release is
intended to be strictly informational and is NEVER to be construed
or interpreted as research material. All readers are
strongly urged to perform research and due diligence on their own
and consult a licensed financial professional before considering
any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the
statements made in this release. FNMG is not liable for any
investment decisions by its readers or subscribers. Investors
are cautioned that they may lose all or a portion of their
investment when investing in stocks.
FNMG HOLDS NO SHARES OF ANY COMPANY
NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E the Securities Exchange Act of 1934, as amended and
such forward-looking statements are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words
such as "may", "future", "plan" or "planned", "will" or "should",
"expected," "anticipates", "draft", "eventually" or "projected".
You are cautioned that such statements are subject to a multitude
of risks and uncertainties that could cause future circumstances,
events, or results to differ materially from those projected in the
forward-looking statements, including the risks that actual results
may differ materially from those projected in the forward-looking
statements as a result of various factors, and other risks
identified in a company's annual report on Form 10-K or 10-KSB and
other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this
release are made as of the date hereof and FNMG undertakes no
obligation to update such statements.
Contact Information:
Company: FN Media Group, LLC
Contact email: editor@financialnewsmedia.com
U.S. Phone: +1-954-345-0611
URL: http://www.financialnewsmedia.com
SOURCE FN Media Group LLC